September 11, 2023 – Effective treatment for lower urinary tract symptoms (LUTS) in men aged 50 or older is associated with a lower risk of death over the next few years, reports a study in the October issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
“We found a small but significant decrease in mortality risk for older men who received medications for treatment of LUTS,” comments lead author Blayne Welk, MD, MSc, of Western University and Lawson Health Research Institute, London, Ont., Canada. “The findings suggest that we may need to view urinary symptoms differently, possibly with an emphasis on earlier treatment.” Dr. Welk’s coauthor was Andrew McClure, MSc.
One-point reduction in urinary symptoms linked to 4% reduction in mortality
The researchers analyzed data on 3,046 men aged 50 years or with moderate to severe LUTS from a previous clinical trial (the Medical Treatment of Prostate Symptoms trial). Participants were randomly assigned to active treatment with medications for LUTS – the alpha-1 blocker doxazosin, the 5-alpha reductase inhibitor finasteride, or a combination of the two – or inactive placebo treatment.
Follow-up data were used to assess the relationship between reduction in urinary symptoms and the risk of death after an average of six years. Severity was assessed using a standard score (the AUA Symptom Score), which rates the impact of LUTS symptoms on a scale from 0 to 35. The patients’ median age was 62 years; 117 men died during the two-year follow-up period.
“Improvement in male LUTS was associated with a reduced risk of death,” the researchers write. For each one-point reduction in symptom score, the relative likelihood (hazard ratio) for death decreased by 4%. Greater symptom reductions were linked to greater reductions risk of death: hazard ratio decreased by 12% with a three-point reduction in symptom score and by 35% with a 10-point reduction in LUTS.
Men assigned to all three active treatment groups had significant reductions in mortality risk, but the placebo group did not. The findings were consistent on further analyses including adjustment for potential confounding factors or for surgical treatment (transurethral prostate resection). Reductions in specific types of symptoms (storage or voiding symptoms) were associated with similar reductions in mortality.
Could earlier treatment for LUTS lower risk of death?
Lower urinary tract symptoms such as weak stream and frequent nighttime urination (nocturia) are very common in older men. Previous studies have linked moderate to severe LUTS to an increased risk of death. The new study is the first to focus on whether improvement in male LUTS may reduce this excess risk of death.
The reduction in mortality in men receiving effective medications may have implications for the approach to treatment for LUTS in older men. Such urinary symptoms are generally viewed as a “benign condition,” treated only if they become a bothersome problem for the patient.
The researchers emphasize that their study cannot determine whether there is a causal relationship between improvement in LUTS symptoms and subsequent mortality risk. If so, then earlier treatment based on symptom scores would be an appropriate strategy – analogous to the long-term reductions in mortality resulting from early treatment for mild increases in blood pressure.
The authors also note that the study did not evaluate the effect of other treatment options, including newer types of selective alpha blockers. Dr. Welk and Mr. McClure conclude: “Further study is necessary to see if early LUTS treatment independently decreases the risk of mortality.”
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
###
About The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.
